Maria Guerra Gomes

Dr. Maria Guerra Gomes


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2025 in Animals
Verified
Journal Article
Open access
PDF file
Maria Guerra GomesMaria Guerra Gomes
Maria Guerra Gomes
Carla Ferreira-BaptistaCarla Ferreira-Baptista
Carla Ferreira-Baptista
Joana BarrosJoana Barros
Joana Barros
Sofia Alves-PimentaSofia Alves-Pimenta
Sofia Alves-Pimenta
Pedro GomesPedro Gomes
Pedro Gomes
Bruno Jorge ColaçoBruno Jorge Colaço
Bruno Jorge Colaço
Stifle joint diseases present a significant challenge in companion animals that often lead to hind limb lameness, with osteoarthritis being a prevalent degenerative condition causing pain and reduced mobility. Regenerative medicine offers a promising avenue for improving treatment outcomes, with a range of emerging therapies showing potential to alleviate symptoms and promote joint health. Among these, hyaluronic acid and platelet-rich plasma have been widely used as intra-articular treatments to enhance joint lubrication, reduce inflammation, and provide symptomatic relief. Interleukin-1 receptor antagonist protein, autologous conditioned serum, and autologous protein solution represent the next generation of regenerative therapies, offering more disease-modifying effects by inhibiting key mediators of joint inflammation. More recently, the MSC-derived secretome has emerged as an innovative, cell-free approach that leverages the diverse bioactive factors secreted by MSCs to support tissue repair and modulate inflammation. This review highlights the evidence base behind these non-cellular orthobiologic treatments for stifle joint disease, aiming to inform veterinary practitioners and owners about available options and their efficacy in supporting conventional treatments.

10 July 2025 in Methods and Protocols
Verified
Journal Article
Open access
PDF file
RARita Araújo
Rita Araújo
Maria Guerra GomesMaria Guerra Gomes
Maria Guerra Gomes
Joana BarrosJoana Barros
Joana Barros
Pedro GomesPedro Gomes
Pedro Gomes
Burn wounds present a significant challenge to both the medical and scientific communities, contributing to the global economic burden on healthcare systems. Due to the complexity and highly variability of burn injuries, along with intricate pathophysiological mechanisms, the development of appropriate and effective treatment strategies remains particularly demanding. The development of robust pre-clinical models that recapitulate specific molecular and cellular events underlying burn injury are essential to advance the understanding of associated biological mechanisms and facilitate the screening of innovative therapeutic interventions. While conventional in vivo models can replicate the key aspects of human burn wound pathology, they are often associated with ethical, logistical, and cost-related limitations. In this context, this study aims to explore the potential of the chicken chorioallantoic membrane (CAM) as an alternative model for burn wound research. Thus, we describe a reproducible and ethically favorable protocol for establishing standardized burn injuries on the CAM and provide a comprehensive evaluation of tissue responses through macroscopic, morphometric, and histological analyses. Our findings support the CAM as a viable pre-clinical platform for the study of burn wound healing and for the early-stage screening of candidate therapeutic agents.

27 October 2025 in Biomedical Materials
Verified
Journal Article
Open access
Maria Guerra GomesMaria Guerra Gomes
Maria Guerra Gomes
LGLiliana Grenho
Liliana Grenho
JCJosé Cunha
José Cunha
FPFrancisco Preto
Francisco Preto
RARita Araújo
Rita Araújo
Pedro GomesPedro Gomes
Pedro Gomes
The clinical use of topical hemostatic agents has become increasingly widespread. While these agents primarily serve to control bleeding, their direct contact with bone and surrounding tissues raises concerns about biological compatibility and potential interference with bone healing and regeneration. Given their growing use in osseous surgical procedures, it is critical to characterize and compare the osteogenic properties of these materials. This study evaluated four commercially available gelatin-based hemostatic sponges: Hemospon®, Clinix®, Gelatamp®, and Octocolagen®, for their osteogenic potential. Leachables derived from each sponge were prepared according to ISO 10993–12:2021 guidelines and tested at 12.5% and 50% concentrations in in vitro assays using human osteoblastic populations. Assessed parameters included metabolic activity, proliferation, osteogenic gene expression, alkaline phosphatase (ALP) activity, and extracellular matrix production. Additionally, intact sponges were directly applied to bone defects in an ex vivo organotypic bone culture model, enabling the tissue characterization within a physiologically relevant environment. Results demonstrated marked material-dependent differences. Gelatamp® significantly enhanced osteogenic gene expression, ALP activity, and matrix production in vitro , and promoted mature collagen deposition ex vivo . Hemospon® also showed favorable, though more limited, effects. Octocolagen® exhibited a neutral biologically profile, while Clinix® consistently impaired osteoblastic activity, gene expression, and extracellular matrix formation in both models. These findings demonstrate that gelatin-based hemostatic agents are not biologically equivalent. Material composition and processing influence their regenerative performance, underscoring the need for informed selection when used in bone-contact surgical applications.

30 April 2026 in Dental and Medical Problems
Verified
Journal Article
Open access
Maria Guerra GomesMaria Guerra Gomes
Maria Guerra Gomes
LGLiliana Grenho
Liliana Grenho
MFMaria Helena V Fernandes
Maria Helena V Fernandes
Pedro GomesPedro Gomes
Pedro Gomes
Bruno Jorge ColaçoBruno Jorge Colaço
Bruno Jorge Colaço
The effective management of hemostasis is essential in surgical practice. Topical hemostatic agents become indispensable when conventional methods are insufficient or impractical. However, the wide range of commercially available products with similar compositional bases presents clinicians with numerous choices and potentially variable performance profiles. Notably, to the best of the authors' knowledge, no previous study has comprehensively compared the biological functionality of these commercially available materials. Addressing this knowledge gap is essential for improving the precision and effectiveness of hemostatic interventions, ultimately contributing to better patient outcomes and advancing healthcare practice. This study aimed to conduct a comprehensive evaluation of the biological response to clinically available gelatin-based hemostatic agents, namely Hemospon®, Clinix®, Gelatamp®, and Octocolagen®. The evaluation encompassed in vitro studies to characterize the response of human fibroblasts upon exposure, together with an in vivo irritation assessment using the hen's egg test - chorioallantoic membrane (HET-CAM) assay, thereby providing a comprehensive understanding of their biological effects. Human fibroblasts were cultured and exposed to the leachables extracted from the hemostatic agents, prepared according to the ISO 10993-12:2021 guidelines, at concentrations of 50%, 25% and 12.5%. The cultures were characterized in terms of cellular viability (the live/dead assay and flow cytometry) and metabolic activity at multiple time points. In addition, irritation potential was evaluated using the HET-CAM assay. Data analysis revealed that the fibroblast cultures exposed to the leachables from the 4 hemostatic sponges proliferated actively throughout the culture period, with minimal evidence of cell death or significant impairment of metabolic activity. Furthermore, no irritant effects were observed in the HET-CAM assay. Overall, despite minor variations in the biological response, the comprehensive analysis supports the overall biocompatibility of commercially available gelatin-based hemostatic sponges. These findings advance the current understanding of the biological safety of these materials, further reinforcing their clinical suitability and highlighting their potential to improve surgical healing outcomes.